KRAS and ovarian cancer: These patients included an ovarian cancer patient with KRAS G12D and EGFR G724S mutations with SD (- 9%) for 7 months and a salivary gland cancer patient with EGFR amplification by IHC with SD (+ 3%) for 5 months.